Meeting
2022 ASCO Annual Meeting
Salvage high-dose chemotherapy (HDCT) for relapsed primary mediastinal nonseminomatous germ-cell tumors (PMNSGCT).
Authors
Fadi Taza
Division of Hematology and Oncology, Indiana University Simon Cancer Center, Indianapolis, IN
Fadi Taza , Rafat Abonour , Sandra K. Althouse , Ryan Ashkar , Mohammad Issam Abu Zaid , Nasser H. Hanna , Kenneth A. Kessler , Nabil Adra , Lawrence H. Einhorn
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Germ Cell/Testicular Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5032)
DOI
10.1200/JCO.2022.40.16_suppl.5032
Abstract #
5032
Poster Bd #
216
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
High doses of chemotherapy and autologous hematopoietic stem cell transplantation in patients with relapsed/refractory testicular germ cell tumors: Multicenter real-world experience in Argentina.
First Author: Federico Losco
Poster
2017 ASCO Annual Meeting
High-dose chemotherapy (HDCT) plus peripheral-blood stem-cell transplant (PBSCT) for patients (pts) with relapsed germ-cell tumors (GCT) and active brain metastases (mets).
First Author: Maitri Kalra
Poster
2014 ASCO Annual Meeting
Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT).
First Author: Yago Nieto
Poster
2024 ASCO Annual Meeting
High dose chemotherapy in male patients with germ cell cancer: A population-based study by the SWENOTECA group.
First Author: Anna Jansson